Board of Directors
Scientific Advisory Board
CHOOSE THE GOLDEN
LIFE SCIENCES BREAKTHROUGHS
Our expert team is the first to examine and evaluate the Hebrew University’s biomedical breakthroughs. We then capitalize decades of experience – transforming the inventions into pioneering companies.
Our golden eggs
A late stage company with a unique lipid-based cytotoxic agent under review by FDA for marketing authorization.
A Phase III company that develops host-directed therapeutics to control life-threatening infections.
A Phase II company that develops a novel approach for delaying or preventing the progression to Alzheimer’s Disease in patients diagnosed with mild cognitive impairment (MCI).
Tiltan Pharma Ldt.
A Phase II company that develops a novel oral formulation of four drugs for solid cancer therapy.
A Phase Ib company that develops a novel liposomal prodrug of a cytotoxic agent for cancer therapy.
A preclinical company with a unique formulation of the widely used anesthetic agent, Propofol, that provides a solution to the main drawback of the commercial product Diprivan, bacterial contamination.
A preclinical stage company that develops novel liposomal formulations of known drugs for post-surgical pain, inflammation and cancer.
A preclinical company developing novel topical non-invasive formulations of approved drugs to ocular uses, targeting major disease states and clinical needs.
Hil Applied Medical Ltd
A medical device company with breakthrough laser-based technology that reduces the size, complexity and cost of proton accelerators, marking a significant leap in radiation therapy.
A preclinical company developing novel antisense oligonucleotides for spesific genetic mutations in Cytic Fibrosis, a disease with great unmet clinical needs.
A preclinical company developing novel monoclonal antibodies targeting novel immune-checkpoint mechanisms in oncology, focusing on the Nectin family of receptors.
The best innovations in Israeli biotech